Form 13-F position report

KINNATE BIOPHARMA INC

Reported by GEODE CAPITAL MANAGEMENT LLC

KNTE CUSIP 49705R105 Manager CIK 0001214717

Reported 0 shares, down 244,151 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 15 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 6443000
2022-03-31 4111000
2022-06-30 5176000
2022-09-30 5027000
2022-12-31 2632000
2023-03-31 2783681
2023-06-30 558862
2023-09-30 310187
2023-12-31 546988
2024-03-31 649569
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for KINNATE BIOPHARMA INC held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Reduced 0 -244,151 (-100.0%) 0 $0 2024-08-09
Q1 2024 Added 244,151 +13,398 (5.8%) < 0.01% $649,569 2024-05-13
Q4 2023 Added 230,753 +9,239 (4.2%) < 0.01% $546,988 2024-02-13
Q3 2023 Added 221,514 +37,071 (20.1%) < 0.01% $310,187 2023-11-13
Q2 2023 Reduced 184,443 -260,946 (-58.6%) < 0.01% $558,862 2023-08-11
Q1 2023 Added 445,389 +13,775 (3.2%) < 0.01% $2,783,681 2023-05-15
Q4 2022 Added 431,614 +10,905 (2.6%) < 0.01% $2,632,000 2023-02-13
Q3 2022 Added 420,709 +10,225 (2.5%) < 0.01% $5,027,000 2022-11-14
Q2 2022 Added 410,484 +45,381 (12.4%) < 0.01% $5,176,000 2022-08-12
Q1 2022 Added 365,103 +1,471 (0.4%) < 0.01% $4,111,000 2022-05-13
Q4 2021 Added 363,632 +26,410 (7.8%) < 0.01% $6,443,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

57 managers reported KINNATE BIOPHARMA INC for Q2 2024.

Managers reporting KINNATE BIOPHARMA INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Skandinaviska Enskilda Banken AB publ Reduced 0 -51,200 0 $0 2 qtrs
DEUTSCHE BANK AG Reduced 0 -114,846 0 $0 14 qtrs
ROYAL BANK OF CANADA Reduced 0 -14 0 $0 15 qtrs
COWEN AND COMPANY LLC Reduced 0 -25,000 0 $0 2 qtrs
VANGUARD GROUP INC Reduced 0 -1,076,789 0 $0 15 qtrs
Tower Research Capital LLC TRC Reduced 0 -1,091 0 $0 14 qtrs
MORGAN STANLEY Reduced 0 -7,427 0 $0 13 qtrs
JANE STREET GROUP LLC Reduced 0 -42,378 0 $0 9 qtrs
RHUMBLINE ADVISERS Reduced 0 -2,933 0 $0 14 qtrs
XTX Topco Ltd Reduced 0 -104,437 0 $0 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 09, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.